NEWS BRIEF · Research journal
Rare GLP1R variants diminish the weight loss effect of semaglutide but not of tirzepatide
From the report
Nature Metabolism, Published online: 13 November 2026; doi:10.1038/s42255-026-01661-2In a large, real-world genomic study, rare damaging variants in the gene encoding the glucagon-like peptide 1 (GLP1) receptor blunted weight loss in people taking semaglutide but had no significant effect on weight loss with tirzepatide, a drug that also targets the glucose-dependent insulinotropic polypeptide (GIP) receptor.
